Proteomics International Pty. Ltd.

Proteomics International (PI) is a pioneering medical technology company operating at the forefront of predictive diagnostics and bio-analytical services. The company specialises in the area of proteomics – industrial scale study of the structure and function of proteins.

PI operates in the following main areas:

PromarkerD – World’s first predictive test for early detection of Diabetic Kidney Disease (DKD). It is a cost-effective, easy-to-use patented technology. The company is in the process of commercialising PromarkerD globally and are currently recruiting licensing, manufacturing, distribution, and testing partners.

Diagnostics – Leverages the power of Promarker™️ platform technology to identify a panel of biomarkers and develop novel intellectual property. The company targets new diagnostic tests in areas of significant unmet needs with enormous markets and revenue potential. PI has a strong pipeline of novel tests in development for a range of ailments such as Endometriosis, Asthma & COPD, Oesophageal Cancer, Gastro, Diabetic Retinopathy and Oxidative Stress etc.

Analytical Services – With growing demand from industry and academia for specialised analytics, the company has developed high-end capabilities in thriving sectors of Pharmacokinetic (PK) testing and Biologics/Biosimilars drug characterisation to cater to the pharmaceutical sector. PI has state-of-the-art capabilities with >$4m invested in cutting-edge facility.

  • Pharmacokinetic Testing – PI applies its proven expertise and experience in targeted mass spectrometry to the field of PK testing. Mass spectrometry is ideal for accurate and precise quantitation of target drugs and their metabolites in biological matrices which is the basis of pharmacokinetic testing. Testing is undertaken in accordance with the principles of GLP.
  • Biologics/Biosimilars Drug Characterisation – Biosimilar development begins with extensive structural and functional characterisation of the drug which underpins all further product development activities. PI operates a world leading ISO/IEC 17025:2005 accredited protein analysis laboratory with a proven track record in characterising Biologics/Biosimilars.
  • Biomarker Discovery, Verification and Validation – The company’s Promarker™ platform uses mass spectrometry-based technology to identify proteins that can be used as biological markers of a particular disease and/or other conditions. Biomarker projects for clients require candidate biomarker discovery, verification, and subsequent validation to identify the most robust biomarkers. Validated biomarkers can then be used in patents, publications and may serve as possible drug targets and/or candidates for development of novel diagnostics.
  • Food QC Testing – PI offers QC testing for food products. It has an analytical services contract with The a2 Milk Company. It undertakes protein analysis for the a2 Milk brand of fresh milk products to:
    • validate protein composition; and
    • for QC purposes

Testing is undertaken in accordance with the principles of GLP

  • Other Proteomics Services:
    • Protein Identification by Mass Spectrometry
    • De Novo Peptide Sequencing
    • Intact Protein Mass Analysis
    • Labelled Relative Quantitation Analysis (iTRAQ / TMT)
    • MRM / SRM (Multiple Reaction Monitoring / Selected Reaction Monitoring) – Targeted Mass Spectrometry
    • Amino Acid Analysis
    • Proteome Mapping MuDPIT Analysis
    • Disulphide Bridge Analysis
    • Protein Flux by In Vivo Stable Isotope Labelling (2H, 15N)
    • Phosphorylation Detection
    • Protein Synthesis and Degradation Rate Measurement
    • Label Free Relative Quantitation Analysis
    • 1-D Gel Electrophoresis